U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO11.ClH
Molecular Weight 579.98
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXORUBICIN HYDROCHLORIDE

SMILES

Cl.[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO

InChI

InChIKey=MWWSFMDVAYGXBV-RUELKSSGSA-N
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C27H29NO11
Molecular Weight 543.5193
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/doxorubicin.html

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

CNS Activity

CNS Non-penetrant
1018
Curator's Comment: Doxorubicin did not have access to areas of the brain within the blood-brain barrier, passed from the blood into the nervous parenchyma in those areas of the brain located outside the blood-brain barrier in mice

Originator

Approval Year

1974
156
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Inhibitor
8146
 2.67 µM [IC50]
A673
6
Target ID: CHEMBL614517
Inhibitor
8146
 200.0 nM [IC50]
Inhibitor
8146
 24.68 µM [IC50]
Inhibitor
8146
 0.074 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

8.1647999E11
Primary
Approved
8307
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

8.1647999E11
Primary
Approved
8307
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

8.1647999E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26115930
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.4 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26115930
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
34.8 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26115930
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
25%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf
DOXORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Other AEs: Mucositis, Chills...
Other AEs:
Mucositis (severe, 1 patient)
Chills (1 patient)
Pyrexia (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Other AEs: Sinus tachycardia, Neutropenia...
Other AEs:
Sinus tachycardia (1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (1 patient)
Mucositis (severe, 1 patient)
Sepsis (severe, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Disc. AE: Tissue injury...
Other AEs: Acute myeloid leukaemia, Myelodysplastic syndrome...
AEs leading to
discontinuation/dose reduction:
Tissue injury (severe)
Other AEs:
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelosuppression (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
300 mg/m2 1 times / 3 weeks multiple, intravenous (total)
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Other AEs: Cardiomyopathy...
Other AEs:
Cardiomyopathy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Chills 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Pyrexia 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Mucositis severe, 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Sinus tachycardia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Thrombocytopenia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Neutropenia grade 4, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Mucositis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Sepsis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: acute lymphoblastic leukemia
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Acute myeloid leukaemia
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Myelodysplastic syndrome
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Myelosuppression severe
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Tissue injury severe
Disc. AE
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Cardiomyopathy
300 mg/m2 1 times / 3 weeks multiple, intravenous (total)
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1491

AKR1C3
10

NDUFS2
6

NDUFS3
6

NDUFS7
6

NQO1
6

XDH
6

MRP1
102

MRP2
196

BCRP
545

SLC22A16
6

MRP5
39

OATP1A2
59

OATP1B1
389

OATP1B3
333
CYP1A1
103

CYP1A2
671

CYP1B1
50

CYP2B2
13

CYP2E1
121

CYP2J3
6

CYP2C11
12

CYP2B1
24

CYP2C23
8
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2B1
39
 no
CYP2C23
8
 no
CYP2C11
13
 weak
CYP1A1
206
 yes
CYP1A2
1620
 yes
CYP1B1
66
 yes
CYP2B2
14
 yes
CYP2E1
929
 yes
CYP2J3
6
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
SLC22A16
6
 yes [Km 5.2 uM]
AKR1C3
10
 yes
BCRP
545
 yes
MRP1
102
 yes
MRP2
196
 yes
MRP5
39
 yes
GS-DOX
6
NDUFS2
6
 yes
NDUFS3
6
 yes
NDUFS7
6
 yes
NQO1
6
 yes
OATP1A2
59
 yes
OATP1B1
389
 yes
OATP1B3
333
 yes
P-gp
1491
 yes
XDH
6
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28748
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28748
MolPort
MolPort-006-124-025
https://www.molport.com/shop/molecule-link/MolPort-006-124-025
ZINC
ZINC000003918087
http://zinc15.docking.org/substances/ZINC000003918087
eMolecules
36788175
https://www.emolecules.com/cgi-bin/more?vid=36788175
PubMed

PubMed

TitleDatePubMed
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
1999
Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine.
1999 Apr
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
1999 Apr 1
Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes.
1999 Aug 1
Doxorubicin cardiotoxicity: growing importance.
1999 Jul
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
1999 Jul
Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.
1999 Jul
Primary desmoplastic small cell tumor of soft tissues and bone of the hand.
1999 Nov
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
1999 Oct
The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats.
2000 Aug
Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats.
2000 Dec
Neural crest-derived defects in experimental esophageal atresia.
2000 Feb
Manic episode in an ifosfamide-treated patient.
2000 Jan-Feb
The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats.
2000 Mar 7
Renal antioxidant enzymes and fibrosis-related markers in the rat adriamycin model.
2000 Oct
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
2000 Sep 15
Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters.
2001 Jan
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
2001 Jan 1
Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2.
2001 Jan 1
Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
2001 Jan 12
Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells.
2001 Jan 26
Mycosis fungoides and pregnancy.
2001 Jan-Feb
Patents

Patents

JP1038021A
6
JP2001511768A
13
JP2001512418A
13
JP2001527049A
10
JP2002504526A
6
JP2002514656A
6
JP2002540172A
6
JP2002541200A
12
JP2002541233A
392
JP2002542270A
9
JP2003503313A
12
JP2003511357A
6
JP2003525696A
6
JP2004523497A
78
JP2004532301A
10
JP2004534728A
75
JP2005528891A
6
JP2006514009A
43
JP2006516548A
15
JP2007508039A
109
JP2007528354A
9
JP2009526755A
434
JP2010515545A
12
JP2010519305A
8
JP2011063524A
6
JP2011178784A
6
JP2011510954A
140
JP2011525180A
172
JP2011528040A
10
JP3300342B2
6
JP4041066B2
9
JP4301440B2
13
JP4527401B2
30
JP4601549B2
17
JP4662473B2
6
JP4672257B2
8
JP4744782B2
6
JP4758474B2
84
JP4790413B2
11
JP4813746B2
10
JP4818917B2
29
JPH01301627A
18
JPH02167294A
6
JPH03251761A
6
JPH0363226A
6
JPH0368595A
6
JPH06107546A
6
JPH06256376A
6
JPH08322582A
6
JPH0834746A
6
JPH11269065A
7

Sample Use Guides

In Vivo Use Guide
When used in combination with other chemotherapy drugs, the most commonly used dosage of doxorubicin is 40 to 60 mg/m2 IV every 21 to 28 days. Alternatively, 60 to 75 mg/m2 IV once every 21 days.
Route of Administration: Intravenous
In Vitro Use Guide
Alkalinization of extracellular pH by urease (2 U/ml) and urea (> or = 2 mM) was found to enhance the antitumor efficacy of doxorubicin (50 uM)
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:49:07 UTC 2022
Edited
by admin
on Fri Dec 16 16:49:07 UTC 2022
Record UNII
82F2G7BL4E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXORUBICIN HYDROCHLORIDE
EMA EPAR   EP   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
IMX-110 COMPONENT DOXORUBICIN HYDROCHLORIDE
Common Name English
(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE HYDROCHLORIDE
Common Name English
ADRIAMYCIN, HYDROCHLORIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP-RS]
Common Name English
Doxorubicin hydrochloride [WHO-DD]
Common Name English
DOXORUBICIN HYDROCHLORIDE [EMA EPAR]
Common Name English
CAELYX
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME [VANDF]
Common Name English
DOXORUBICINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [MART.]
Common Name English
DOXIL
Brand Name English
DOXORUBICIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
HYDROXYDAUNOMYCIN HYDROCHLORIDE
Common Name English
DOXORUBICIN HCL
Common Name English
DOXORUBICIN HYDROCHLORIDE [VANDF]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-IP]
Common Name English
ADRIAMYCIN
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME
VANDF  
Common Name English
ADRIABLASTINA CS
Common Name English
ADRIAMYCIN [IARC]
Common Name English
RUBEX
Brand Name English
5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYLACETYL)-1-METHOXY-, HYDROCHLORIDE (8S-CIS)-
Common Name English
Liposomal doxorubicin hydrochloride [WHO-DD]
Common Name English
DOXORUBICIN LIPOSOMAL COMPLEX OF THE HYDROCHLORIDE [MI]
Common Name English
DOXORUBICIN HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/833
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
NCI_THESAURUS C67502
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
EMA ASSESSMENT REPORTS MYOCET (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
FDA ORPHAN DRUG 229006
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
FDA ORPHAN DRUG 191704
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
FDA ORPHAN DRUG 210705
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
FDA ORPHAN DRUG 628318
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
FDA ORPHAN DRUG 311910
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
Code System Code Type Description
ECHA (EC/EINECS)
246-818-3
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
FDA UNII
82F2G7BL4E
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
CHEBI
28748
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
MERCK INDEX
M4757
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY Merck Index
RXCUI
142433
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DOXORUBICIN HYDROCHLORIDE
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY Description: A red-orange, crystalline powder. Solubility: Soluble in water and methanol R; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Doxorubicin hydrochloride should be kept in a tightly closed container. Additional information: Doxorubicin hydrochloride is hygroscopic; it is poisonous: CAUTION: Doxorubicin hydrochloride must behandled with care, avoiding contact with the skin and inhalation of airborne particles. Definition. Doxorubicin hydrochloride contains not less than 97.0% and not more than 102.0% of C27H29NO11,HCl, calculatedwith reference to the anhydrous substance.
EVMPD
SUB06391MIG
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
RS_ITEM_NUM
1225703
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
DAILYMED
82F2G7BL4E
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
CAS
25316-40-9
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
PUBCHEM
443939
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
ChEMBL
CHEMBL53463
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
NCI_THESAURUS
C1326
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
RXCUI
466523
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
ALTERNATIVE
EVMPD
SUB01827MIG
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
EVMPD
SUB126795
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
ALTERNATIVE
DRUG BANK
DBSALT000060
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
EPA CompTox
DTXSID3030636
Created by admin on Fri Dec 16 16:49:07 UTC 2022 , Edited by admin on Fri Dec 16 16:49:07 UTC 2022
PRIMARY
Related Record Type Details
Structure of DOXORUBICIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Acetone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of DOXORUBICINONE
IMPURITY -> PARENT
Structure of DAUNOMYCINONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DAUNORUBICIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of DOXORUBICIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966